With the demand for intensive therapy and tight glycemic control increases the risk of hypoglycemia, which can lead to death. Hypoglycemia is because of the limitations of successful therapy.
Hypoglycaemia is consistent patient education, self-monitoring and the use of newer opportunities and new therapy of diabetes mellitus first and 2nd type. Therapy reduces insulin analogues demonstrable risk of hypoglycemia.
Therapies based on incretins significantly reduces the risk of hypoglycemia, since the treatment shows the same risk of hypoglycemia with placebo. A new drug for the treatment of diabetes therapy improves safety by reducing the risk of hypoglycemia.